Summary for Tradename: REZULIN
Clinical Trials for: REZULIN
Troglitazone in Treating Patients With Liposarcoma
Status: Active, not recruiting Condition: Sarcoma
TART - Troglitazone Atherosclerosis Regression Trial
Status: Completed Condition: Atherosclerosis; Diabetes Mellitus
To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies
Status: Completed Condition: Type 2 Diabetes Mellitus; Impaired Glucose Tolerance
Fracture Risk With Thiazolidinediones
Status: Completed Condition: Fractures, Bone; Type II Diabetes
Glibenclamide (Dose to be Titrated From Starting Dose of 5mg om) Plus Rosiglitazone 4mg om (Increased to 8mg om After 6 Months) and vs Glibenclamide (Dose to be Titrated With Starting Dose of 5mg om) Plus Placebo, Administered to Patients With Type 2 Diabetes Mellitus
Status: Completed Condition: Diabetes Mellitus, Type 2
Association Study of Genetic Polymorphisms of Candidate Genes With Thiazolidinedione-Related Peripheral Edema and Drug Responsiveness
Status: Recruiting Condition: Diabetes Mellitus
Diabetes Prevention Program Outcomes Study
Status: Active, not recruiting Condition: Diabetes Mellitus
Courtesy of ClinicalTrials.org
See more clinical trials for this drug
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||Type||RLD||Patent No.||Patent Expiration||Product||Substance||Delist Req.||Exclusivity Expiration|
|TABLET;ORAL||020720||Aug 4, 1997||DISCN||No||5,602,133||<disabled>||<disabled>|
|TABLET;ORAL||020720||Aug 4, 1997||DISCN||No||5,859,037||<disabled>||<disabled>|
|TABLET;ORAL||020720||Aug 4, 1997||DISCN||No||6,011,049||<disabled>||<disabled>|
|TABLET;ORAL||020720||Aug 4, 1997||DISCN||No||6,046,202||<disabled>||<disabled>|
|This preview shows a limited data set|
Complete access is available with a Subscription
Export unavailable in trial.
Subscribe for complete access.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639